Marein
Based on 3 publication(s) in Google Scholar
Marein has the neuroprotective effect due to a reduction of damage to mitochondria function and activation of the AMPK signal pathway. Marein improves insulin resistance induced by high glucose in HepG2 cells through CaMKK/AMPK/GLUT1 to promote glucose uptake, through IRS/Akt/GSK-3β to increase glycogen synthesis, and through Akt/FoxO1 to decrease gluconeogenesis. Marein is a HDAC inhibitor with an IC50 of 100 μM. Marein has beneficial antioxidative, antihypertensive, antihyperlipidemic and antidiabetic effects.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.65%
- CAS No.: 535-96-6
- Formule: C21H22O11
- Masse moléculaire:450.39
-
Stockage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
-
Solvant et solubilité
- Pureté et documentation
- Références
-
Help & FAQs
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Epigenetics Compound Library
HY-L005
-
PI3K/Akt/mTOR Compound Library
HY-L015
-
Natural Product Library
HY-L021
-
Histone Modification Research Compound Library
HY-L024
-
Anti-Aging Compound Library
HY-L034
-
Antioxidant Compound Library
HY-L037
-
Reprogramming Compound Library
HY-L039
-
Anti-diabetic Compound Library
HY-L040
-
Glycoside Compound Library
HY-L042
-
Oxygen Sensing Compound Library
HY-L045
-
Anti-Cardiovascular Disease Compound Library
HY-L046
-
Phenols Library
HY-L057
-
Glycolysis Compound Library
HY-L058
-
Cytoskeleton Compound Library
HY-L060
-
Flavonoids Library
HY-L068
-
Neuroprotective Compound Library
HY-L070
-
Anti-Breast Cancer Compound Library
HY-L074
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Blood Cancer Compound Library
HY-L079
-
Anti-Cancer Metabolism Compound Library
HY-L083
-
Anti-Obesity Compound Library
HY-L087
-
Transcription Factor-Targeted Library
HY-L090
-
Lipid Metabolism Compound Library
HY-L091
-
Glucose Metabolism Compound Library
HY-L092
-
Anti-Liver Cancer Compound Library
HY-L101
-
Plant-Sourced Natural Product Library
HY-L115
-
Osteogenesis Compound Library
HY-L131
-
Heterocyclic Compound Library
HY-L138
-
Pain-Related Compound Library
HY-L139
-
Antihypertensive Compound Library
HY-L145
-
Anti-Drug-Resistant Compound Library
HY-L169
-
Anti-Hematopathy Compound Library
HY-L171
-
Multi-Target Compound Library
HY-L176
-
Radioprotector Library
HY-L178
-
Bioactive Compound Library Max
HY-L181
-
Natural Product Library Plus
HY-L021P
-
Natural Product and Natural Product-Like Compound Library
HY-L021M
-
Bioactive Compound Library
HY-L001
-
Anti-Brain Cancer Compound Library
HY-L188
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
Lactic Acid Metabolic Compound Library
HY-L204
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Throughput Natural Product Library
HY-L206
-
High-Efficiency Gene Editing Compound Library
HY-L244
-
Lactylation Compound Library
HY-L249
-
Mass Spectrometry Natural Product Library
HY-L262
Publications Citing Use of MedChemExpress (MCE) Marein
MoreVoir tous les produits spécifiques à Isoform AMPK
More
Activité biologique
IC50: 100 µM (HDAC)[3]
Marein (0-1000 μM; 24 h) inhibits HDAC activity and TNFα-induced NF-κB activation with IC50 values of 100 and ＞200 μM, respectively[1]. Marein (1.25-40 μM; 24 h) promotes glucose uptake in HepG2 cells[2]. Marein (5-10 μM; 24 h) promotes GLUT1 translocation from intercellular vesicles to the plasma membrane, increases hepatic glycogen content and down-regulates expression levels of G6Pase and PEPCK in HepG2 cells[2]. Marein (5-10 μM; 24 h) stimulates 2-NBDG uptake, and it can be reduced by STO-609 and compound C which is a inhibitor of AMPK[2]. Marein (0-40 μM; 24 h) affects the cytotoxicity of MG in PC12 cells[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HepG2 cell line
-
Concentration:5 and 10 μM
-
Incubation Time:24 hours
-
Result:Increased GLUT1 translocation to plasma membrane and decreased the phosphorylation level of AS160 and GSK-3β in HepG2 cells.
-
Cell Line:HepG2 cell line
-
Concentration:10 μM
-
Incubation Time:0-10 hours
-
Result:Time- and dose-dependently induced phosphorylation of AMPK and Akt in HepG2 cells.
-
Cell Line:PC12 cell line
-
Concentration:0-40 μM
-
Incubation Time:24 hours
-
Result:Prevened MG-induced loss of viability in PC12 cells.
-
Cell Line:PC12 cell line
-
Concentration:5-10 μM
-
Incubation Time:30 min
-
Result:Protected PC12 cells from MG-induced apoptosis.
-
Cell Line:PC12 cell line
-
Concentration:5-10 μM
-
Incubation Time:30 min
-
Result:Increased phospho-AMPKα (Thr172) in PC12 cells.
Chemical Information
-
CAS No. 535-96-6
-
Appearance Solid
-
Masse moléculaire 450.39
-
Formule C21H22O11
-
Color Yellow to orange
-
SMILES
O=C(C1=CC=C(O[C@H]2[C@@H]([C@H]([C@@H]([C@@H](CO)O2)O)O)O)C(O)=C1O)/C=C/C3=CC=C(O)C(O)=C3
-
Structure Classification
-
Initial Source
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Int Immunopharmacol
2024 Nov 27:144:113695. PMID: 39608176 -
Cardiovasc Toxicol
Marein Alleviates Doxorubicin-Induced Cardiotoxicity through FAK/AKT Pathway Modulation while Potentiating its Anticancer Activity. [Abstract]2024 Aug;24(8):818-835. PMID: 38896162 -
J Mol Histol
Marein alleviates atherosclerosis by inhibiting macrophage ferroptosis through activating NRF2 pathway. [Abstract]2025 Sep 30;56(5):332. PMID: 41026310
Solvant et solubilité
DMSO : ≥ 100 mg/mL (222.03 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (5.55 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (5.55 mM); Clear solution
This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Pureté et documentation
-
Fiche technique (278 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. B Orlikova, et al. Natural chalcones as dual inhibitors of HDACs and NF-κB. Oncol Rep. 2012 Sep;28(3):797-805. [Content Brief]
[2]. Baoping Jiang, et al. Protective effects of marein on high glucose-induced glucose metabolic disorder in HepG2 cells. Phytomedicine. 2016 Aug 15;23(9):891-900. [Content Brief]
[3]. Baoping Jiang, et al. Marein protects against methylglyoxal-induced apoptosis by activating the AMPK pathway in PC12 cells. Free Radic Res. 2016;50(11):1173-1187. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.2203 mL | 11.1015 mL | 22.2030 mL | 55.5074 mL |
| 5 mM | 0.4441 mL | 2.2203 mL | 4.4406 mL | 11.1015 mL | |
| 10 mM | 0.2220 mL | 1.1101 mL | 2.2203 mL | 5.5507 mL | |
| 15 mM | 0.1480 mL | 0.7401 mL | 1.4802 mL | 3.7005 mL | |
| 20 mM | 0.1110 mL | 0.5551 mL | 1.1101 mL | 2.7754 mL | |
| 25 mM | 0.0888 mL | 0.4441 mL | 0.8881 mL | 2.2203 mL | |
| 30 mM | 0.0740 mL | 0.3700 mL | 0.7401 mL | 1.8502 mL | |
| 40 mM | 0.0555 mL | 0.2775 mL | 0.5551 mL | 1.3877 mL | |
| 50 mM | 0.0444 mL | 0.2220 mL | 0.4441 mL | 1.1101 mL | |
| 60 mM | 0.0370 mL | 0.1850 mL | 0.3700 mL | 0.9251 mL | |
| 80 mM | 0.0278 mL | 0.1388 mL | 0.2775 mL | 0.6938 mL | |
| 100 mM | 0.0222 mL | 0.1110 mL | 0.2220 mL | 0.5551 mL |
Marein Related Classifications
HY-N7676 Related Classifications
Powered by Bioz